| 1889-08-15 |
Born in Itose Village, Nyu District, Fukui Prefecture, founder Toyoji Naito was born. |
| 1905 |
Toyo departs his hometown at age 15 and moves to Osaka. |
| 1906 |
Toyo joins Winkel Trading Company, where he learns English, German, Chinese, and bookkeeping. |
| 1909 |
Toyo leaves Winkel Trading Company and joins the Imperial Guard's Second Regiment at Kudan, Tokyo. |
| 1911 |
After discharge, Toyo joins Tamson Trading Company, which handles imported pharmaceuticals. |
| 1914 |
|
| 1915 |
Toyo moves to Tokyo and joins Tanabe Motozaburo Shoten (now Tanabe Mitsubishi Pharma). |
| 1917 |
Toyo conducts a approximately 7-month inspection tour of Southeast Asia. |
| 1918 |
|
| 1921 |
Toyo develops fragrant castor oil 'Castarol' and massage medicine 'Salomethyl' at Tanabe Motozaburo Shoten. |
| 1923 |
The Great Kanto Earthquake occurs, causing Tanabe Motozaburo Shoten to suffer significant damage including the loss of its main store. |
| 1924 |
Toyo handles Japan's first blood pressure lowering drug 'Animaza' at Tanabe Motozaburo Shoten. The catchphrase 'High Blood Pressure' was created by Toyo. |
| 1933 |
The newspaper advertisement for 'Salomethyl' developed by Toyo wins the top prize at the 1st Newspaper Advertisement Encouragement Society Awards. |
| 1936 |
Established the partnership company 'Sakuragaoka Laboratory' in Tokyo. |
| 1937 |
Toyo inspects the pharmaceutical industries of Europe and America. |
| 1938 |
Launched Vitamin E product 'Ubera'. |
| 1939 |
|
| 1941 |
Established Japan Eizai Co., Ltd. in Saitama Prefecture, Honjo Town. |
| 1944 |
Sakuragaoka Laboratory and Japan Eizai merge through an equal partnership to form Japan Eizai Co., Ltd. |
| 1945 |
|
| 1950 |
Contraceptive 'Sampoon Tablets' passes national examination amid post-war baby boom. |
| 1952 |
Launch of high-dose B1 agent 'Chocola BB Tablets'. |
| 1955 |
|
| 1957 |
|
| 1961 |
Established Taipei Branch in Taiwan, listed on the First Section of Tokyo and Osaka Stock Exchanges, launched stomach medicines 'Sakuron' and 'Sakuron Tablets'. |
| 1964 |
|
| 1966 |
Kawashima Factory opens in Gifu Prefecture. Haruo Naito becomes Chairman, Yuji Naito becomes President. |
| 1969 |
|
| 1970 |
Sakuragaoka Laboratory and Japan Eizai merge into Japan Eizai through an equal partnership. |
| 1971 |
Japan's first 'Medicine Museum' opens in Gifu Prefecture. |
| 1973 |
The first oil shock occurs due to the Middle East War. |
| 1974 |
Established sales companies in Malaysia and the Philippines, launched metabolic inotropic agent 'Noikino'. |
| 1977 |
Launched natural-type Vitamin E agent 'Yubelax'. |
| 1978 |
Passed away at age 89. |
| 1979 |
Established a sales support and management service company in Singapore. |
| 1981 |
Established a sales company and factory in California, USA. Opened Misato Factory in Saitama Prefecture, introduced large automatic coating equipment. |
| 1982 |
|
| 1983 |
Established Eisai Chemistry Co., Ltd. for active pharmaceutical ingredient manufacturing. |
| 1984 |
Launched 'Cerevox', a gastric ulcer treatment drug, in Japan. |
| 1987 |
Started sponsoring the Medical Merit Award (until 2015). |
| 1988 |
Yuji Naito assumes the position of Chairman. Haruo Naito becomes President. |
| 1990 |
|
| 1991 |
Established a pharmaceutical sales company in Hong Kong, a liaison office and joint venture in China. Celebrated 50th founding anniversary. |
| 1992 |
Formulated corporate philosophy and Human Health Care (HHC). |
| 1993 |
Research institute in London completed, attended by Princess Anne. |
| 1995 |
Established pharmaceutical sales companies in the US, UK, and Germany. |
| 1996 |
Established sales and manufacturing companies in Paris, France, and Suzhou, China. Also established a generic pharmaceutical company. |
| 1997 |
Established a life sciences research institute in Kobe. Set up sales company in Korea. Completed formulation research and production facility in the US. Launched Alzheimer's drug 'Aricept'. |
| 1998 |
Launched 'Aricept' in France. Launched 'Pariet' in the UK and Germany. |
| 1999 |
Launched 'Acefex' in the US. Launched 'Aricept' in Japan. |
| 2001 |
|
| 2002 |
Started the Millennium Plan. |
| 2004 |
Transitioned to a committee-based company, established European headquarters, and set up sales company in India. |
| 2005 |
Established sales companies in Italy, Switzerland, and Sweden. Clarified corporate philosophy. Yuji Naito passed away. |
| 2006 |
Established sales company in Australia. Acquired 'Ligand' anticancer drug. |
| 2007 |
Established manufacturing company in the UK. Acquired biotech venture. Established research and manufacturing company in India. Established sales company in Belgium. |
| 2008 |
Launched rheumatoid arthritis treatment 'Humira' in Japan. |
| 2009 |
Established sales company in Austria, opened European Knowledge Center, established Eisai Knowledge Center India. Built a global research and development system. |
| 2010 |
Kozukawa Knowledge Center completed. Launched 'Haraven' in the US. |
| 2011 |
The Great East Japan Earthquake occurred. Started the 6th Mid-term Strategy 'Hayabusa'. Established sales companies in Brazil and Mexico. |
| 2012 |
London Declaration, Haruo Naito became President of Japan Pharmaceutical Association, launched 'Fycompa' in Europe. |
| 2013 |
Established sales company in Moscow, Russia. Participated in development support fund. Provided free treatment for lymphatic filariasis to WHO. |
| 2014 |
Launched 'Fycompa' in the US. Established a holding company in China. |
| 2015 |
Launched 'Lenvima' in US, Japan, and Europe. Acquired Liaoning Tianyi Biological Pharmaceutical in China. |
| 2016 |
Started the 7th Mid-term Business Plan 'EWAY2025'. Launched 'Ficonpa' in Japan. |
| 2017 |
Participated in non-communicable disease initiatives. Supported lymphatic filariasis. Expanded Alzheimer's treatment collaborations. |
| 2018 |
Agreed on strategic partnership for 'Lenvima'. Fully operationalized Suzhou factory in China. Launched 'Lenvima' in China. |
| 2019 |
Launched G2D2 in the US. Launched 'Exfina' for Parkinson's in Japan. Launched 'Ficonpa' and 'Haraven' in China. |
| 2020 |
WHO declared COVID-19 pandemic. Launched self-check tool 'NOU KNOW'. Launched sleep disorder drug 'Deebigo' in US and Japan. Established bases in China and Vietnam. |
| 2021 |
Started 8th Mid-term Strategy 'EWAY Future & Beyond'. Approved 'ADUHELM' in US. Expanded collaborations. Hosted Tokyo Olympics. Celebrated 80th anniversary. |
| 2022 |
Transitioned to a committee-based company, established European headquarters, and set up sales company in India. |
| 2023 |
Approved and launched 'LEQEMBI' in US. Contributed to fund. Fully approved 'LEQEMBI'. Established digital business company. Launched 'Leqembi' in Japan. |
